Provided by Tiger Fintech (Singapore) Pte. Ltd.

Irhythm Technologies Inc.

100.34
-5.5800-5.27%
Post-market: 100.340.00000.00%19:36 EDT
Volume:405.55K
Turnover:40.51M
Market Cap:3.15B
PE:-27.63
High:102.95
Open:101.65
Low:96.66
Close:105.92
Loading ...

Company Profile

Company Name:
Irhythm Technologies Inc.
Exchange:
NASDAQ
Establishment Date:
2006
Employees:
2000
Office Location:
699 8th Street,Suite 600,San Francisco,California,United States
Zip Code:
94103
Fax:
- -
Introduction:
iRhythm Technologies, Inc., a digital healthcare company, engages in the design, development, and commercialization of device-based technology to provide ambulatory cardiac monitoring services to diagnose arrhythmias in the United States. It offers Zio services, an ambulatory monitoring solution, including long-term and short-term continuous monitoring and mobile cardiac telemetry monitoring services. The company also provides the Zio Monitor System, a prescription-only, remote electrocardiogram (ECG) monitoring system that consists of a patch ECG monitor that records the electric signal from the heart continuously for up to 14 days and the Zio ECG Utilization Software System, which supports the capture and analysis of ECG data recorded by the Zio Monitor patch at the end of the wear period, including specific arrhythmia events detected by the ZEUS System; the Zio XT System is the previous generation of the Zio Monitor System and is a prescription-only, remote ECG monitoring system that consists of the Zio XT patch that records the electric signal from the heart continuously for up to 14 days; and the Zio AT system, a prescription-only, remote ECG monitoring system that similarly consists of the Zio AT patch that records the electric signal from the heart continuously for up to 14 days and the ZEUS System, but which also incorporates the Zio AT wireless gateway that provides connectivity between the Zio AT patch and the ZEUS System during the patient wear period. It has a development collaboration agreement with Verily Life Sciences LLC and Verity Ireland Limited to develop various next-generation atrial fibrillation screening, detection, or monitoring products. The company was incorporated in 2006 and is headquartered in San Francisco, California.

Directors

Name
Position
Abhijit Y. Talwalkar
Director and Chairman of the Board
Quentin S. Blackford
President, Chief Executive Officer, Director
Bruce G. Bodaken
Director
Cathleen Noel Bairey Merz
Director
Karen Ling
Director
Mark J. Rubash
Director
Ralph Snyderman
Director
Renee Budig
Director

Shareholders

Name
Position
Quentin S. Blackford
President, Chief Executive Officer, Director
Douglas J. Devine
Chief Financial Officer and Chief Operating Officer
Daniel G. Wilson
Executive Vice President of Strategy, Corporate Development and Investor Relations
David A. Vort
Executive Vice President, Sales
Mark J. Day
Executive Vice President of Research & Development